The Philippines Department of Science and Technology-Philippine Council for Health Research and Development (DOST-PCHRD) has approved a clinical trial investigating the use of an herbal medicine called “lagundi” as a therapeutic supplement for COVID-19. The study was also cleared by the University of the Philippines (UP) Manila Research Ethics Board, reports DOST Secretary Fortunato de la Peña. Interestingly, this government research agency issued a press release prior to securing that nation’s FDA approval.
The Study still Needs Philippine FDA Approval
Secretary de la Peña recently told the Philippine News Agency (PNA), “the project aims to determine if lagundi, as adjuvant therapy, can provide symptomatic relief for mild COVID-19 patients without co-morbidities.” It also aims to determine if lagundi can decrease the number of patients who progress from mild to moderate or severe cases.
Interestingly, the information about this study was released by the DOST-PCHRD prior to approval by the Food and Drug Administration (FDA) of the Philippines. The DOST-PCHRD Secretary told the Philippines press, “The FDA will further evaluate and ensure full protection of human subjects’ ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).